Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Group of Clinicians Protests against Asahi Shimbun for Reports on Vaccine Clinical Trial
November 8, 2010
- Shionogi, Sawai Settle Patent Infringement Lawsuit for Flomox
November 8, 2010
- Anti-Histaminic Xyzal Approved: GSK
November 8, 2010
- Chugai Develops New Technology to Produce Reusable MAb
November 8, 2010
- Generics May Save ¥200 Mil. Per Month: Kyokaikenpo
November 8, 2010
- Revolade Approved for ITP: GSK
November 8, 2010
- Chugai Presents Data on Eldecalcitol from Japanese Patients
November 8, 2010
- Japan-India EPA Not Intended to Preferentially Treat Applications from Indian Companies: Korosho
November 8, 2010
- MINCLEA Approved for Pretreatment for Endoscopy: Nihon Pharma
November 8, 2010
- TAK-442 Fails to Show Efficacy in Multinational PII Trial: Takeda
November 8, 2010
- FDA Approves DSP's Schizophrenia Drug Lurasidone
November 8, 2010
- Lyrica Approved for Pain Due to Peripheral Neuropathy: Pfizer Japan
November 8, 2010
- Hizentra Shows Efficacy, Safety in PIII in Europe
November 8, 2010
- Eisai's Botulinum Toxin B, DSP's Repaglinide Recommended for Approval
November 8, 2010
- Benesis Obtains Additional Indication for Venoglobulin: MTPC
November 8, 2010
- Kobayashi Medical Falsifies Application Data for 2 Implant Products
November 8, 2010
- Only APIs Used for 1 Year or More on the Market to Be Approved for Use in Combination Drugs
November 8, 2010
- Botox Approved for Lower/Upper Limb Spasticity: GSK
November 8, 2010
- Erbitux Achieves OS of 28.3 Months in Wild-Type KRAS Tumor Patients
November 8, 2010
- Applications Based on Data from Public Domain Recommended for 3 APIs by 2nd Committee
November 8, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…